-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Qilu Pharmaceutical has two Class 1 new drugs approved for clinical trials, namely the imported VB4-845 injection and the domestic Class 1 new drug QLS31901 for injection.
Source: CDE official website
The two innovative drugs approved by Qilu Pharmaceuticals recently are all anti-tumor drugs.
VB4-845 injection is an antibody-drug conjugate (ADC) developed by Sesen Bio.
At the end of July 2020, Qilu Pharmaceutical and Sesen Bio reached an exclusive licensing agreement to obtain the exclusive development and commercialization rights of the product in Greater China (Mainland China, Hong Kong, Macau and Taiwan) for a cooperative transaction amount of US$35 million.
Since 2021, Qilu Pharmaceutical has applied for clinical or approved new drugs for marketing
Source: Meinenet MED2.
According to data from Meinenet, since 2021, Qilu Pharmaceutical has applied for clinical application of 3 new drugs of Class 1 and 2 of them have been approved for clinical use.
Source: Minet database, CDE official website
Note: The statistics are as of March 22.